Sjorgren's Syndrome
Conditions
Keywords
Mesenchymal stem/stromal cell, MSC, Advanced Therapy Medicinal Product (ATMP),, xerostomia, dry mouth, Sjogren's disease, Sjogren's syndrome, randomized clinical trial (RCT)
Brief summary
Living with dry mouth significantly impacts daily life, causing constant discomfort. It makes it harder to talk, eat solid food (increasing the risk of malnutrition), swallow, and sleep well. It also raises the risk of tooth decay. One common cause of dry mouth is Sjögren's Syndrome. Sjögren's Syndrome is a common chronic autoimmune disease. In this disease, the immune system attacks the body's own saliva glands, reducing saliva production and leading to severe dry mouth and its associated symptoms. Current treatments for dry mouth are temporary and only last a short time (from a few minutes to a few hours). Therefore, new treatment options are needed. Research has shown that mesenchymal stem cells can be used to treat dry mouth with promising results. These stem cells can be injected into a vein or directly into the saliva glands. Although the exact mechanism is not fully understood, studies suggest that stem cells can positively affect the immune system, reduce inflammation, regenerate tissue, and reverse scarring. This research group has been studying stem cell treatment for dry mouth for over 10 years and is internationally recognized. The group have conducted three studies where we injected stem cells into the saliva glands of patients with dry mouth due to radiation therapy for head or neck cancer. Results showed a 30%-50% increase in saliva production and a significant reduction in dry mouth symptoms. No studies have yet investigated injecting stem cells into the saliva glands of patients with dry mouth due to Sjögren's Syndrome. One study did inject stem cells into tear glands with promising results. Therefore, this study aim to investigate injecting stem cells into the saliva glands of patients with dry mouth due to Sjögren's Syndrome. For this study, mesenchymal stem cells harvested from the fat tissue of healthy adult donors is used. This type of stem cell is better at reversing scarring and forming new blood vessels. The procedure is quick and has few side effects, and donors benefit from the fat removal. The fat is typically taken from the abdominal area. Donors are tested for various diseases to ensure they are healthy. Previous studies have shown that the treatment is safe with only a few temporary side effects. The hypothesis is that injecting stem cells into the saliva glands of patients with dry mouth due to Sjögren's Syndrome will improve saliva production and reduce dry mouth symptoms. The study aims to determine if this treatment increases saliva production and reduces symptoms caused by dry mouth. To test these hypotheses, the study will include: 1. The treatment itself with either stem cells or a placebo (sterile saline). 2. Multiple saliva tests to measure saliva production. 3. Saliva samples stored for later analysis to see if the saliva's ability to protect teeth and aid digestion changes after stem cell treatment. 4. A blood test to examine the immune system's response to the stem cell treatment. 5. A clinical examination to see if the stem cell treatment affects Sjögren's Syndrome symptoms elsewhere in the body. 6. Questionnaires to assess participants' perceptions of changes in dry mouth symptoms after treatment. The treatment involves injecting either stem cells or a placebo into the two saliva glands near the jaw, guided by an ultrasound scan. The procedure takes 10 minutes. Although stem cell treatment has been shown to be safe, safety will be monitored in this study. At all three visits, participants will be asked about any side effects, which will be categorized as serious or mild, and as treatment-related or not. Follow-up and treatment plans will be made for any side effects. Participants will also always have direct access to the treating doctor. The study will be monitored by the Danish Medicines Agency and the GCP unit, which ensures that all rules and laws are followed.
Interventions
DRUGMSC
Allogeneic adipose-derived mesenchymal stromal / stem cells in 10% DMSO
Isotonic sterile saline water
Sponsors
Rigshospitalet, Denmark
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients diagnosed with SS according to the American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) classification criteria for primary SjD (2) 2. Age equal or above 18 years 3. Persistent xerostomia for at least 3 months 4. Unstimulated whole saliva flow rate (UWS) of minimum 0.05 ml/min and maximum 3.0 ml/min 5. Capable and willing to receive proper information and to give written informed consent.
Exclusion criteria
1. Current intake of xerogenic medications such as anticholinergics, tricyclic antidepressants, opioids, and certain antihypertensive agents (23) 2. Presence of any other diseases of the salivary glands, e.g. xerostomia due to radiation 3. Previous submandibular gland surgery 4. Previous treatment with any type of stem cells in the salivary glands 5. Pregnancy or planned pregnancy within the 12 months study period 6. Breastfeeding 7. Tobacco smoking within the previous 6 months from screening visit 8. Have a current alcohol abuse (consumption must not exceed 10 units per week (Danish National board health alcohol guidelines (24)) 9. Any other disease/condition judged by the investigator to be grounds for exclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in unstimulated whole saliva flow rate by sialometry | From baseline to 4 months after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| • Safety evaluated by number of serious adverse events (SAE), adverse advents (AE), and deaths | From baseline to 4 and 12 months after treatment | — |
| Quality of the whole saliva measured as changes in percentages in the concentration of electrolytes, total protein, alpha-amylase, and salivary IgA with Elisa assays | From baseline to 4 and 12 months after treatment | The concentrations of the specific electrolyte, total protein and IgA will be compared to reference values. |
| Immune response measured by the development of donor specific antibodies | From baseline to 4 and 12 months after treatment | Serum will be frozen until the end of the trial and all samples will be analyzed together. The blood samples will be analyzed for HLA class I and class II antibodies with the Luminex platform (Luminex 200 system or LABScan3D) and will be reported as HLA antibodies present/not present in the samples. |
| Lacrimal secretion measured by the Schirmers Test | From baseline to 4 and 12 months after treatment | — |
| • Changes in the gland morphology as assessed by ultrasound | From baseline to 4 and 12 months after treatment | Measured as changes in the OMERACT US system |
| Change in stimulated whole saliva flow rate by sialometri | From baseline to 4 and 12 months after treatment | — |
| • Changes in ESSPRI | From baseline to 4 and 12 months after treatment | — |
| PROM: Xerostomia Questionnaire | From baseline to 4 and 12 months after treatment | This PROM will be compared by converting to summary-scores ranging from 0-100. |
| PROM:Clinical Oral Dryness score. | From baseline to 4 and 12 months after treatment | This outcome will be compared by converting to summary-scores ranging from 0-100 |
| PROM: Summated Xerostomia Inventory. | From baseline to 4 and 12 months after treatment | This outcome will be compared by converting to summary-scores ranging from 0-100 |
| • Changes in ESSDAI | From baseline to 4 and 12 months after treatment | — |
Countries
Denmark
Contacts
Primary ContactJoachim Hansen, M.D, PhD-fellow
Outcome results
None listed